I

I-MAB
D

IMAB

4.23000
USD
-0.12
(-2.76%)
مغلق
حجم التداول
33,263
الربح لكل سهم
-0
العائد الربحي
-
P/E
-8
حجم السوق
487,575,404
أصول ذات صلة الأخبار المقالات

العنوان: I/MAB

القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).